{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"26"}]}],"title":"Progression of disease overall"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Skeletal-related events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"24"}]}],"title":"Progression to stage II or III"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"}]}],"title":"Unequivocal progression of osteolytic lesion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"description":"Number of patients with progression by individual criteria consisting of Progression of disease overall, Skeletal-related events (including pathological fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or Hypercalcemia), Progression to stage II or III according to Salmon \\& Durie classification, and unequivocal progression of osteolytic lesion. Patients are counted separately for every type of progression, but only once for Overall Progression.","groups":[{"description":"Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.","id":"OG000","title":"Zoledronic Acid (ZOL446)"},{"description":"No Treatment with study medication.","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"48 months","title":"Number of Patients With Progression by Individual Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}